Advertisement

Annals of Surgical Oncology

, Volume 17, Issue 8, pp 2066–2072 | Cite as

Prognostic Value of Perineural Invasion in Patients with Stage II Colorectal Cancer

  • Jung Wook Huh
  • Hyeong Rok KimEmail author
  • Young Jin Kim
Colorectal Cancer

Abstract

Background

Perineural invasion (PNI) may influence the prognosis after resection of colorectal cancer (CRC); whether this is a definite prognostic factor remains controversial. This study determined the clinicopathologic factors associated with oncologic outcome after radical resection of stage II CRC, focusing on PNI.

Materials and Methods

We retrospectively reviewed 341 consecutive patients who underwent curative surgery for stage II CRC between January 2001 and December 2006. Of these, 278 patients (81.5%) received postoperative 5-fluorouracil-based chemotherapy. The oncologic outcomes and the risk factors for recurrence were analyzed.

Results

PNI was detected in 57 of 341 patients (16.7%) and was significantly associated with depth of tumor invasion (P = .035) and positive lymphovascular invasion (P < .001). Multivariate analyses revealed that PNI was a significant independent prognostic factor for disease-free survival, not for overall survival. With a median follow-up period of 57.6 months, the 5-year disease-free and overall survival rates of the patients were 80.2 and 82.6%, respectively. The 5-year disease-free survival of the PNI-negative group was significantly higher than that of the PNI-positive group (P < .001). Within the PNI-positive patients, those receiving chemotherapy had significantly higher 5-year disease-free survival than the others (P = .023).

Conclusion

This study illustrates the value of PNI as a prognostic factor for stage II CRC. Moreover, PNI-positive patients should be considered for postoperative chemotherapy.

Keywords

Adjuvant Chemotherapy Perineural Invasion Postoperative Chemotherapy Circumferential Resection Margin Oral Fluoropyrimidines 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This work was supported by a grant from Chonnam National University Research Institute of Medical Sciences and a Research Grant 0720570 from the National Cancer Center, South Korea.

References

  1. 1.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Engstrom PF, Benson AB III, Chen YJ, Choti MA, Dilawari RA, Enke CA, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:468–91.PubMedGoogle Scholar
  3. 3.
    Norum J. Adjuvant chemotherapy in Dukes’ B and C colorectal cancer has only a minor influence on psychological distress. Support Care Cancer. 1997;5:318–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Kato A, et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer. 1998;82:274–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Fujita S, Nakanisi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y, et al. Cancer invasion to Auerbach’s plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer. Dis Colon Rectum. 2007;50:1860–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Di Fabio F, Nascimbeni R, Villanacci V, Baronchelli C, Bianchi D, Fabbretti G, et al. Prognostic variables for cancer-related survival in node-negative colorectal carcinomas. Dig Surg. 2004;21:128–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer. Br J Surg. 2001;88:994–1000.CrossRefPubMedGoogle Scholar
  8. 8.
    Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001;44:1682–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17:1349–55.PubMedGoogle Scholar
  10. 10.
    Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004;22:484–92.PubMedGoogle Scholar
  11. 11.
    Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.CrossRefPubMedGoogle Scholar
  12. 12.
    Newland RC, Dent OF, Chapuis PH, Bokey L. Survival after curative resection of lymph node negative colorectal carcinoma. A prospective study of 910 patients. Cancer. 1995;76:564–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer. 2001;92:1435–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51:503–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsai HL, Cheng KI, Lu CY, Kuo CH, Ma CJ, Wu JY, et al. Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection. J Surg Oncol. 2008;97:383–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer. 1998;83:666–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42:167–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Mulcahy HE, Toner M, Patchett SE, Daly L, O’Donoghue DP. Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum. 1997;40:326–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol. 2010 [Epub ahead of print].Google Scholar
  20. 20.
    Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.CrossRefPubMedGoogle Scholar
  21. 21.
    Yun HR, Kim HC, Lee WY, Cho YB, Yun SH, Chun HK. The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. Am J Surg. 2009;198:354–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg. 2002;235:458–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Wong JH, Bowles BJ, Bueno R, Shimizu D. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon Rectum. 2002;45:1341–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Murphy J, Pocard M, Jass JR, O’Sullivan GC, Lee G, Talbot IC. Number and size of lymph nodes recovered from dukes B rectal cancers: correlation with prognosis and histologic antitumor immune response. Dis Colon Rectum. 2007;50:1526–34.CrossRefPubMedGoogle Scholar
  25. 25.
    McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191–203.CrossRefPubMedGoogle Scholar
  26. 26.
    Huh JW, Kim HR, Lee JH, Kim YJ. Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis. Virchows Arch. 2009;454:381–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, et al. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009;59:241–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Huh JW, Kim HR, Kim YJ. Proliferating cell nuclear antigen as a prognostic factor after total mesorectal excision of stage II-III rectal cancer. Ann Surg Oncol. 2009;16:1494–500.CrossRefPubMedGoogle Scholar
  29. 29.
    Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003;21:241–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–206.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Jung Wook Huh
    • 1
  • Hyeong Rok Kim
    • 1
    Email author
  • Young Jin Kim
    • 1
  1. 1.Department of SurgeryChonnam National University Hwasun Hospital and Medical SchoolGwangjuKorea

Personalised recommendations